Epcoritamab-bysp
Brand names: Epkinly · Active ingredient: Epcoritamab
In short: EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved
What is Epcoritamab-bysp used for?
EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate and durability of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
EPKINLY is indicated in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
EPKINLY is indicated as monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.
âš Boxed warning (FDA's strongest warning)
Cytokine release syndrome (CRS), including serious or fatal reactions, can occur in patients receiving EPKINLY. Initiate treatment with the EPKINLY step-up dosage schedule to reduce the incidence and severity of CRS. Withhold EPKINLY until CRS resolves or permanently discontinue based on severity .
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), including life-threatening and fatal reactions, can occur with EPKINLY. Monitor patients for neurological signs or symptoms of ICANS during treatment. Withhold EPKINLY until ICANS resolves or permanently discontinue based on severity .
Epcoritamab-bysp dosage
Certain doses of EPKINLY require dilution prior to administration. There are 2 available methods to prepare diluted EPKINLY:
Empty sterile vial method as described in subsection 2.7 , or
Sterile syringe method as described in subsection 2.8 .
Preparation of 3 mg and 48 mg EPKINLY doses does not require dilution. .
EPKINLY should only be administered by a qualified healthcare professional with appropriate medical support to manage severe reactions such as CRS and ICANS .
Administer EPKINLY to well-hydrated patients.
Premedicate before each dose in Cycle 1 .
Administer EPKINLY subcutaneously according to the recommended step-up dosage schedule to reduce the incidence and severity of CRS .
Due to the risk of CRS and ICANS, monitor all patients for signs and symptoms . Assess whether hospitalization or outpatient monitoring is appropriate based on comorbidities or other situational factors for the first 48 mg dosage of EPKINLY for patients with:
DLBCL or high-grade B-cell lymphoma: on Cycle 1 Day 15 .
FL: on Cycle 1 Day 22 .
EPKINLY is for subcutaneous injection only.
The recommended DLBCL dosage for Cycle 1 consists of 2 step-up doses, and the recommended FL dosage (monotherapy or in combination with lenalidomide and rituximab) consists of 3 step-up doses.
EPKINLY as Monotherapy:
Administer EPKINLY in 28-day cycles until disease progression or unacceptable toxicity.
Indication | CycleCycle = 28 days. | Day | Dose of EPKINLY
DLBCL or High-grade B-cell Lymphoma | Cycle 1 | 1 | Step-up dose 1 | 0.16 mg
8 | Step-up dose 2 | 0.8 mg
15 | First full dose | 48 mg
22 | 48 mg
Cycles 2 and 3 | 1, 8, 15 and 22 | 48 mg
Cycles 4 to 9 | 1 and 15 | 48 mg
Cycle 10 and beyond | 1 | 48 mg
Indication | CycleCycle = 28 days. | Day | Dose of EPKINLY
Follicular Lymphoma | Cycle 1 | 1 | Step-up dose 1 | 0.16 mg
8 | Step-up dose 2 | 0.8 mg
15 | Step-up dose 3 | 3 mg
22 | First full dose | 48 mg
Cycles 2 and 3 | 1, 8, 15 and 22 | 48 mg
Cycles 4 to 9 | 1 and 15 | 48 mg
Cycle 10 and beyond | 1 | 48 mg
EPKINLY in Combination with Lenalidomide and Rituximab:
Administer EPKINLY in 28-day cycles for a total of 12 cycles or until disease progression or unacceptable toxicity, whichever occurs first.
Indication | CycleCycle = 28 days. | Day | Dose of EPKINLY
Follicular Lymphoma | Cycle 1 | 1 | Step-up dose 1 | 0.16 mg
8 | Step-up dose 2 | 0.8 mg
15 | Step-up dose 3 | 3 mg
22 | First full dose | 48 mg
Cycles 2 and 3 | 1, 8, 15, and 22 | 48 mg
Cycles 4 to 12 | 1 | 48 mg
Administer EPKINLY in combination with lenalidomide 20 mg (Days 1 to 21 in Cycles 1 to 12) and rituximab 375 mg/m2 (Cycles 1 to 5) . …
How to take Epcoritamab-bysp — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Cytokine Release Syndrome (CRS)
Inform patients of the risk of CRS, and to immediately contact their healthcare provider should signs and symptoms associated with CRS (e.g., pyrexia, hypotension, hypoxia, chills, tachycardia, headache, and dyspnea) occur at any time. Advise patients with DLBCL or high-grade B-cell lymphoma that they may be hospitalized after administration of the Cycle 1 Day 15 dosage of 48 mg and patients with FL after administration of the Cycle 1 Day 22 dosage of 48 mg. Patients who receive Cycle 1 Day 15 and patients who receive Cycle 1 Day 22 first full dosage of 48 mg at an outpatient facility should remain in proximity of a healthcare facility that can assess and manage CRS afterwards. Advise all patients who experience symptoms that impair consciousness not to drive and refrain from operating heavy or potentially dangerous machinery until events resolve . …
Warnings & precautions
Do not take this medicine if: None.
EPKINLY can cause CRS, including serious or fatal reactions .
Relapsed or Refractory Large B-cell Lymphoma
CRS occurred in 51% (80/157) of patients with LBCL receiving EPKINLY at the recommended dosage schedule in EPCORE NHL-1, with Grade 1 CRS occurring in 37%, Grade 2 in 17%, and Grade 3 in 2.5% of patients. Recurrent CRS occurred in 31% of these patients. Most CRS events (92%) occurred during Cycle 1. In Cycle 1, CRS events occurred in 6% of patients after the 0.16 mg dose, 12% after the 0.8 mg dose, 43% after the first 48 mg dose, and 5% after the next 48 mg dose. The median time to onset of CRS from the most recent EPKINLY dose was 24 hours (range: 0 to 10 days). The median time to onset after the first 48 mg dose was 21 hours (range: 0 to 7 days).
For patients with LBCL, assess whether hospitalization or outpatient monitoring for the first 48 mg dose (Cycle 1 Day 15) is appropriate based on comorbidities or other situational factors . During outpatient monitoring after the first 48 mg dose, patients should remain in proximity to a healthcare facility that can assess and manage CRS.
Relapsed or Refractory Follicular Lymphoma
CRS occurred in 49% (42/86) of patients with FL receiving EPKINLY monotherapy at the recommended dosage schedule in EPCORE NHL-1, with Grade 1 CRS occurring in 45% and Grade 2 in 9% of patients. Recurrent CRS occurred in 48% of patients. Most CRS events (88%) occurred during Cycle 1. In Cycle 1, CRS events occurred in 12% of patients after the 0.16 mg dose, 6% after the 0.8 mg dose, 15% after the 3 mg dose, and 37% after the first 48 mg dose. The median time to onset of CRS from the most recent EPKINLY dose was 59 hours (range: 0.1 to 7 days). The median time to onset after the first 48 mg dose was 61 hours (range: 0.1 to 7 days). …
Epcoritamab-bysp side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Cytokine Release Syndrome .
Immune Effector Cell-Associated Neurotoxicity Syndrome .
Infections .
Cytopenias .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Relapsed or Refractory Large B-cell Lymphoma (LBCL)
EPCORE NHL-1
The safety of EPKINLY was evaluated in EPCORE NHL-1, a single-arm study of patients with relapsed or refractory LBCL after two or more lines of systemic therapy, including DLBCL not otherwise specified, DLBCL arising from indolent lymphoma, high grade B-cell lymphoma, and other B-cell lymphomas . A total of 157 patients with LBCL received EPKINLY via subcutaneous injection until disease progression or unacceptable toxicities according to the following 28-day cycle schedule:
Cycle 1: EPKINLY 0.16 mg on Day 1, 0.8 mg on Day 8, 48 mg on Days 15 and 22
Cycles 2-3: EPKINLY 48 mg on Days 1, 8, 15, and 22
Cycles 4-9: EPKINLY 48 mg on Days 1 and 15
Cycles 10 and beyond: EPKINLY 48 mg on Day 1
Of the 157 patients treated, the median age was 64 years (range: 20 to 83), 60% were male, and 97% had an ECOG performance status of 0 or 1. …
Drug interactions
For certain CYP substrates, minimal changes in the concentration may lead to serious adverse reactions. Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with EPKINLY.
Epcoritamab-bysp causes release of cytokines that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. Increased exposure of CYP substrates is more likely to occur after the first dose of EPKINLY and up to 14 days after the first 48 mg dose, and during and after CRS .
About this medicine
Epcoritamab-bysp is a bispecific CD20-directed CD3 T-cell engager; it is a humanized bispecific IgG1 antibody. Epcoritamab-bysp is manufactured in Chinese hamster ovary (CHO) cells using recombinant DNA technology and has an approximate molecular weight of 149 kDa.
EPKINLY (epcoritamab-bysp) injection for subcutaneous use is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution, free of visible particles.
Each single-dose 4 mg/0.8 mL vial contains epcoritamab-bysp (4 mg), acetic acid (0.19 mg), polysorbate 80 (0.32 mg), sodium acetate (1.7 mg), sorbitol (21.9 mg) and Water for Injection, USP. The pH is 5.5.
Each single-dose 48 mg/0.8 mL vial contains epcoritamab-bysp (48 mg), acetic acid (0.19 mg), polysorbate 80 (0.32 mg), sodium acetate (1.7 mg), sorbitol (21.9 mg) and Water for Injection, USP. The pH is 5.5.
How it works: Epcoritamab-bysp is a T-cell engaging bispecific antibody that binds to the CD3 receptor expressed on the surface of T-cells and CD20 expressed on the surface of lymphoma cells and healthy B-lineage cells. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d7836711-b677-412d-bf2d-0f7c8444103a. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate